

## 平成 21 年度 海外研修員 研修報告

慶應義塾大学医学部 精神神経科学教室 岸本泰士郎

2009年10月より2013年3月まで、アメリカ、ニューヨーク The Zucker Hillside Hospital, Psychiatry Research にて留学させて頂きました。同院では Drs. John M. Kane, Christoph, U. Correll に師事し、種々の臨床研究に携わらせていただきました。

### 研究テーマ

1. 抗精神病薬の副作用・代謝系副作用
2. 抗精神病薬の副作用・プロラクチン、性ホルモン、骨代謝への影響
3. 初発エピソード統合失調症患者のリカバリー
4. 思春期気分障害のフォローアップ（双極性障害の前駆症状を同定する）
5. 医師の薬物選択における Decision Making
6. Two-Way Video システムを用いた薬剤性 EPS の評価

### Awards and Honors

02/2011	Psychiatric Research Society Annual Meeting; Travel Award
04/2011	Workshop on Clinical Trials (hosted by American Society of Clinical Pharmacology); Travel Award
06/2011	NCDEU 2011 meeting; New Investigator Award
06/2011	NCDEU 2011 meeting; Best Poster Award
02/2012	Psychiatric Research Society Annual Meeting; Travel Award
04/2012	Schizophrenia International Research Society, Biennial Meeting, Florence, Italy; Travel Award
04/2012	Schizophrenia International Research Society, Biennial Meeting, Florence, Italy; Poster Award Finalist
12/2012	American College of Neuropsychopharmacology, Annual Meeting, Hollywood Florida, USA: 2 <sup>nd</sup> place in 218 presentations by poster vote
02/2013	The International Society for CNS Clinical Trials and Methodology, Washington DC, USA: ISCTM special recognition

### Publication

1. Correll C, Kishimoto T, Carlson H. Review: most antipsychotic drugs more than double the prolactin levels in children and adolescents. Evid Based Ment Health. 2010 May;13(2):54.
2. Correll CU, Shaikh L, Gallego JA, Nachbar J, Olshanskiy V, Kishimoto T, Kane JM. Antipsychotic polypharmacy: A survey study of prescriber attitudes, knowledge and

- behavior. *Schizophr Res.* 2011 Sep;131(1-3):58-62.
3. Correll CU, Kishimoto T, Kane JM. Randomized controlled trials in schizophrenia: opportunities, limitations, and trial design alternatives. *Dialogues in Clinical Neuroscience.* 2011;13(2):155-72.
  4. Correll CU, Kishimoto T, Nielsen J, Kane JM. Quantifying clinical relevance in the treatment of schizophrenia. *Clin Ther.* 2011 Dec;33(12):B16-39
  5. Kishimoto T, Agarwal V, Kishi T, Leucht S, Kane JM, Correll CU. Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics. *Mol Psychiatry.* 2013 Jan;18(1):53-66.
  6. Kishimoto T, De Hert M, Carlson HE, Manu P, Correll CU. Osteoporosis and fracture risk in people with schizophrenia. *Curr Opin Psychiatry.* 2012 Sep;25(5):415-429. PubMed PMID: 22744405.
  7. Abbs B, Achalia RM, Adelufosi AO, Aktener AY, Beveridge NJ, Bhakta SG, Blackman RK, Bora E, Byun MS, Cabanis M, Carrion R, Castellani CA, Chow TJ, Dmitrzak-Weglarz M, Gayer-Anderson C, Gomes FV, Haut K, Hori H, Kantrowitz JT, Kishimoto T, Lee FH, Lin A, Palaniyappan L, Quan M, Rubio MD, Ruiz de Azúa S, Sahoo S, Strauss GP, Szczepankiewicz A, Thompson AD, Trotta A, Tully LM, Uchida H, Velthorst E, Young JW, O'Shea A, Delisi LE. The 3rd Schizophrenia International Research Society Conference, 14-18 April 2012, Florence, Italy: Summaries of oral sessions. *Schizophr Res.* 2012 Oct;141(1):e1-e24. Epub 2012 Aug 19. PubMed PMID: 22910407
  8. Kane JM, Kishimoto T, Correll CU. Management of the Treatment Resistant Patient with Schizophrenia. (in press) UpToDate. <http://www.uptodate.com/index>
  9. Kishimoto T, Robenzadeh A, Leucht C, Leucht S, Watanabe K, Mimura M, Borenstein M, Kane JM, Correll CC. Long-acting injectable vs. oral antipsychotics for relapse prevention in schizophrenia: A meta-analysis of randomized trials. *Schizophrenia Bulletin* (in press)
  10. Kane JM, Kishimoto T, Correll CU. The Comparative Effectiveness of Long-Acting Injectable vs. Oral Antipsychotic Medications in the Prevention of Relapse: A Case Study in CER in Psychiatry. *J Clin Epidemiol.* In press
  11. Kane JM, Kishimoto T, Correll CU. Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies. *World Psychiatry.* In Press
  12. Kishimoto T, Watanabe K, Uchida H, Mimura M, Kane JM, Correll CU. Antipsychotic Polypharmacy: A Japanese Survey of Prescribers' Attitudes and Rationales. *Psychiatry Research* (2013 in press)
  13. Takahashi T, Uchida H, John M, Hirano J, Watanabe K, Mimura M, Correll C, Kishimoto T. The impact of prolactin-raising antipsychotics on bone mineral density in patients with

schizophrenia: Findings from a longitudinal observational cohort. Schizophrenia research (2013 in press)

14. Hirano J, Watanabe K, Suzuki T, Uchida H, Den R, Kishimoto T, Nagasawa T, Tomita Y, Hara K, Ochi H, Kobayashi Y, Ishi M, Fujita A, Kanai Y, Goto M, Hayashi H, Inamura K, Ooshima F, Sumida M, Ozawa T, Sekigawa K, Nagaoka M, Yoshimura K, Konishi M, Inagaki A, Saito T, Motohashi N, Mimura M, Ookubo Y, Kato M. An open-label study of algorithm-based treatment versus treatment-as-usual for patients with schizophrenia. Neuropsychiatric Disease and Treatment (in press)
15. 他3本 和文論文

### **Publication Under Review/In Preparation**

16. Kishimoto T, Nitta M, Borenstein M, Kane JM, Correll CU. Long Acting Injectable vs. Oral Antipsychotics in Schizophrenia: A Systematic Review and Meta-Analysis of Mirror-Image Studies (under review)
17. Kishimoto T, Russ MJ, Sanghani S, Marsh A, Morris J, Basu S, John M, Kane JM. Indications for and Use of Long Acting Injectable Antipsychotics: Consideration from an Inpatient Setting (under review)
18. Correll CU; Olvet D; Auther AM, Hauser M; Kishimoto T; Carrion R, Synder S, Cornblatt BA. The Bipolar Prodrome Symptom Scale-Pro prospective (BPSS-P): Scale Description and Validation in a Clinical High-Risk Psychiatric Sample and Healthy Controls (under review)
19. Kishimoto T, Russ MJ, Sanghani S, Marsh A, Morris J, Basu S, Kane JM. Clinical utilization of clozapine, a chart review study (in preparation)
20. Chaula J, Kishimoto T, Correll CU. Ketamin for Major Depressive Episode: A Meta-Analysis. (in preparation)
21. Stentebjerg-Olesen M, Jeppesen P, Pagsberg AK, Fink-Jensen A, Kapoor S, Chekuri R, Carbon M, Kishimoto T, Kane JM, Correll CU. Early-Non-Response Determined By the Clinical Global Impressions Scale Predicts Poorer Outcomes in Youth with Schizophrenia-Spectrum Disorders Naturalistically Treated with Second-Generation Antipsychotics (Under Review)
22. Kishimoto T, Nitta M, Borenstein M, Kane JM, Correll CU. Long Acting Injectable vs. Oral Antipsychotics in Schizophrenia: A Systematic Review and Meta-Analysis of Naturalistic Observational Studies (in preparation)

### **Invited Lectures**

- 05/2011            “Relapse Prevention in Schizophrenia: Meta-Analyses of Efficacy and Predictors” Grand Round The Zucker Hillside Hospital, Glen Oaks, NY,

- USA, May 4<sup>th</sup>, 2011
- 06/2011 “Relapse Prevention in Schizophrenia: Meta-Analyses and Review” Grand Round at Rockland Psychiatric Center, Orangeburg, NY 10962, June 1, 2011, USA
- 06/2011 “Relapse Prevention in Schizophrenia: answering 4 questions derived from clinical practice” Research Seminar at the Sagamore Children’s Psychiatric Center, Dix Hills, NY, USA. June 23<sup>rd</sup> 2011
- 01/2012 “Relapse Prevention in Schizophrenia: Meta-Analysis of Medication Efficacy and Predictors” Grand Rounds lecture at the State University of New York (SUNY) Downstate Medical Center, Brooklyn, New York. January 18<sup>th</sup>
- 01/2012 “Relapse Prevention in Schizophrenia: Meta-Analysis of Medication Efficacy and Predictors” Grand Rounds lecture at Pilgrim Psychiatric Center, West Brentwood, New York. January 25<sup>th</sup>
- 12/2012 “Long Acting Injectable Antipsychotics and Clozapine: Evidence-Based but Underutilized Drugs”, Presentation as a panelist in “Strategy to Reduce Readmissions” meeting. Participants: Psychiatric hospitals and clinics in NY state. Sponsor/Organizer: New York State Office of Mental Health/NYSPI
- 01/2013 “Long Acting Injectable Antipsychotics: Evidence and Utilization” Grand Rounds lecture at Queens Hospital Center, Jamaica, NY. January 18<sup>th</sup> 2013
- 02/2013 “Long Acting Injectable Antipsychotics: Evidence and Clinical Utilization” Grand Rounds lecture at The Zucker Hillside Hospital, Glena Oaks, NY. February 27<sup>th</sup> 2013

### **Oral Presentations**

- 02/2010 Kishimoto T, Kane J, Correll C. Antipsychotic Drugs and Prolactin Dysregulation: What are the Risks? Psychiatric research society Annual meeting, Park City, Utah, U.S.A. February 6, 2010
- 02/2011 Kishimoto T. Relapse Prevention in Schizophrenia: Meta-Analyses of Efficacy and Predictors. Psychiatric research society Annual meeting (**Travel Award**), park city, Utah, U.S.A. February 9-12, 2011
- 02/2012 Kishimoto T. Methodological issues in the study of long acting injectable antipsychotics: review and meta-analysis. Psychiatric Research Society annual meeting (**Travel Award**), Park City, Utah, USA. Feb 8-11, 2012
- 04/2012 Kishimoto T. New Results Alter Balance of Evidence in Meta-analysis of Long-Acting Injectable vs. Oral Antipsychotics in Schizophrenia, Symposium

- in Schizophrenia International Research Society in Florence, Italy
- 04/2012 Kishimoto T. Relapse Prevention in Schizophrenia: Meta-analysis of Long-Acting Injectable vs. Oral Antipsychotics. Symposium in Schizophrenia International Research Society in Florence, Italy
- 05/2012 Kishimoto T. Clinical Relevance of Treatments for Schizophrenia. (Oral presentation in a symposium; “Keeping it Real: Quantifying Clinical Relevance in Treatments for Psychiatric Disorders”, “Clinical Relevance in the Treatment of Schizophrenia”, NCDEU, Phoenix, Arizona, USA May 29-June 1.
- 12/2012 Kishimoto T. Long acting injectable vs. oral antipsychotics in schizophrenia: A systematic review of mirror-image studies. American College of Neuropsychopharmacology (ACNP) 51<sup>st</sup> Annual meeting, 12/2-6/2012, Hollywood, Florida Hollywood, Florida, USA (12/4/2012 Oral presentation in Data Blitz Session)